Lead Product(s): Niclosamide
Therapeutic Area: Infections and Infectious Diseases Product Name: UNI91103
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
UNION therapeutics A/S (UNION) has been selected by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge to trial UNI91103 as a prophylactic treatment of COVID-19 in kidney patients, a vulnerable and high-risk patient population.
Lead Product(s): GBS-NN
Therapeutic Area: Infections and Infectious Diseases Product Name: GBS-NN
Highest Development Status: Phase II Product Type: Vaccine
Deal Size: $57.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 15, 2020
Proceeds will advance the clinical development of MinervaX’s novel GBS vaccine through Phase II clinical trials, as well as manufacturing and regulatory preparation for Phase III.